Patents by Inventor Xiaoxing WU

Xiaoxing WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SHP2 and CDK4/6 dual-target inhibitory compound and pharmaceutical composition containing the same
    Patent number: 12331058
    Abstract: The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three compounds of general formulas I-III and pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. According to the present invention, a class of brand-new SHP2 and CDK4/6 dual-target inhibitors are prepared by means of a pharmacophore fusion and reasonable drug design method, so that the problems of drug resistance, poor drug effect, etc., of the existing SHP2 inhibitor and CDK4/6 inhibitor are solved; the great significance of the present invention is providing the first SHP2 and CDK4/6 dual-target inhibitor, which provides a basis for solving the problem of drug resistance of kinase and phosphatase in the later period.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: June 17, 2025
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Xiaoxing Wu, Xiaoyu Chen, Wenqiang Li, Chengxia Shu, Guangmei Luo, Kexin Yang
  • SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
    Publication number: 20250026756
    Abstract: The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three compounds of general formulas I-III and pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. According to the present invention, a class of brand-new SHP2 and CDK4/6 dual-target inhibitors are prepared by means of a pharmacophore fusion and reasonable drug design method, so that the problems of drug resistance, poor drug effect, etc., of the existing SHP2 inhibitor and CDK4/6 inhibitor are solved; the great significance of the present invention is providing the first SHP2 and CDK4/6 dual-target inhibitor, which provides a basis for solving the problem of drug resistance of kinase and phosphatase in the later period.
    Type: Application
    Filed: July 21, 2022
    Publication date: January 23, 2025
    Applicant: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Xiaoxing WU, Xiaoyu CHEN, Wenqiang LI, Chengxia SHU, Guangmei LUO, Kexin YANG